Quintiles And Biogen Idec Enter Clinical Development Agreement
By Cyndi Root
Quintiles and Biogen Idec have announced in a press release that they have agreed to form a five-year drug development partnership. Quintiles is a CRO and Biogen Idec is a biotechnology company focused on neurodegenerative diseases, hemophilia, and autoimmune disorders. The collaboration takes advantage of the experience and expertise of both companies to optimize clinical trial efficiency.
Tom Pike, CEO of Quintiles said, “Our partnership with Biogen Idec exemplifies the ongoing evolution of drug development collaboration and reinforces the increasingly important role that biopharmaceutical service providers…have in these efforts.”
Alfred Sandrock, CMO at Biogen Idec says that partnership with Quintiles will help the company develop new therapies and carry them through clinical trials. Sandrock says, “As we have continued to build our research and development organization, it was important for us to identify a strong clinical development partner to complement our focus on developing innovative therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases.”
Quintiles and Biogen Idec Agreement
The new agreement calls for a dedicated team from Quintiles to work with Biogen Idec on Phase I through Phase IV studies. The team will assist in designing trials and executing clinical trials. The two companies are already working on new projects while current Biogen Idec studies are transitioning to Quintiles consulting, and management. Biogen Idec will be able to access Quintiles’ services, systems, and technologies.